Verastem, Inc. (VSTM)

NCM – Цена в реальном времени. Валюта: USD

6.94

-0.11 (-1.56%)

Рынок открыт: Aug 12, 2026, 2:26 PM EDT

6.70

-0.35 (-4.96%)

Предыдущая сессия: Aug 11, 2026, 7:47 PM EDT

07.08.2026

Verastem Q2 Earnings Call Highlights

Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance.

07.08.2026

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

06.08.2026

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.39 per share a year ago.

06.08.2026

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts and in.

Видео

No Data

There is no data to display

Пресс-релизы

06.08.2026

Verastem, Inc. (VSTM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Verastem, Inc. (VSTM)

Verastem Q2 Earnings Call Highlights

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Видео

No Data

Пресс-релизы

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Q2 Earnings Call Highlights

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Видео

No Data

Пресс-релизы

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Search stocks

Verastem, Inc. (VSTM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Verastem, Inc. (VSTM)

Verastem Q2 Earnings Call Highlights

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Видео

No Data

Пресс-релизы

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Q2 Earnings Call Highlights

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Видео

No Data

Пресс-релизы

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates